Atazanavir - Isotope Labelled Standards
References
FAQ's
References
- Fassler, Alexander; Bold, Guido; Capraro, Hans-Georg; Lang, Marc; Khanna, Satish Chandra, Antivirally active heterocyclic azahexane derivatives, Novartis A.-G., Switzerland, US5849911A, December 15,1998
- Schuster, A.; Burzawa, S.; Jemal, M.; Loizillon, E.; Couerbe, P.; Whigan, D., Quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human plasma by liquid chromatography-tandem mass spectrometry following automated solid-phase extraction, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Volume: 788, Issue: 2, Pages: 377-386, 2003
Frequently Asked Questions
What is the role of analytical testing in detecting Atazanavir impurities?
Analytical testing helps detect impurities in Atazanavir by providing accurate and reliable data on their presence and concentration.
Do impurities in Atazanavir affect its therapeutic efficacy?
Impurities in Atazanavir can affect its therapeutic efficacy by reducing the drug's potency or altering its mechanism of action.
How can Atazanavir impurities be controlled during the storage of the drug?
The impurities in Atazanavir are controlled during storage by ensuring appropriate temperature, humidity, and light conditions, using proper packaging and storage containers.
What are the temperature conditions required to store Atazanavir impurities?
Atazanavir impurities are stored at a controlled room temperature between 2-8 °C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.